Thermo Fisher Scientific Showcases Solutions for Accelerating Next Generation Vaccine and Therapy Research and Unlocking Deeper Analytical Insights

The company announces new mass spectrometry instruments, workflows, software and industry collaborations during ASMS 2022 Conference MINNEAPOLIS–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, is showcasing new instruments, workflows, software and industry collaborations that enable customers to generate new analytical insights and accelerate next generation vaccine and therapy development. The... Read more

Bruker Launches timsTOF HT with Greater Dynamic Range for Further Enhancing Unbiased, High-Confidence 4D Proteomics™

4th-generation TIMS XR cell with even greater dynamic range can identify more than 100k unique peptides with 60 min gradients at one microgram protein loads, with high-confidence at 1% FDR and without antigen cross-reactivity Increased dynamic range plus new 14-bit digitizer offer excellent quantitation with <5% protein CVs for many proteins in three-proteome mixture Co-distribution... Read more

Bruker Announces Key Innovations for Highly Multiplexed Spatial Proteomics and Multiomic Tissue Imaging at Large Field-of-View

Fast, large field-of-view MALDI HiPLEX-IHC imaging of targeted proteins, overlaid with unbiased small molecule MALDI Imaging on fresh frozen or FFPE tissues offers compelling innovation for spatial biology and cancer research New microGRID technology for timsTOF fleX platform for MALDI positioning provides virtually artifact-free images across entire slide down to 5 µm SCiLS™ Lab 2023a... Read more

Bruker Introduces Novel Point-of-Need Applied Mass Spectrometry Tools for Accelerated Measurements without Chromatography

Recent acquisition of DART™ (Direct Analysis Real-time Technology) innovator IonSense extends Bruker’s unique Point-of-Need (PoN) mass spectrometers Launch of DART-EVOQ® triple quadrupole mass spectrometer offers simple, robust, yet sensitive and specific PoN workflows for applied markets New Bruker strategic partnership with TOFWERK AG brings together skills and vision for next-generation high-speed, ultra-sensitive analytical solutions MINNEAPOLIS–(BUSINESS... Read more

Thermo Fisher Scientific Releases Corporate Social Responsibility Report

Report highlights progress toward environmental, social and governance objectives WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company’s commitment to society and stakeholders providing detailed insight into the company’s CSR progress and environmental, social and governance... Read more

Bruker Corporation to Present at Jefferies 2022 Global Healthcare Conference

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) announced today it will present at the Jefferies 2022 Global Healthcare Conference in New York on Thursday, June 9, 2022 at 3:00 pm EDT. Presenting for the company will be Frank Laukien, President and Chief Executive Officer, and Justin Ward, Sr. Director, Investor Relations & Corporate Development. A... Read more

PerkinElmer Expands Genomic Testing Services with Ultrarapid Whole Genome Sequencing

Latest addition to Company’s genomic testing services menu delivers rapid results to physicians that inform clinical management and outcomes for critically ill patients WALTHAM, Mass. – May 16, 2022 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the availability of ultrarapid whole genome sequencing (urWGS) through PerkinElmer Genomics.... Read more

Bruker Announces Quarterly Dividend

BILLERICA, Massachusetts–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on June 17, 2022 to stockholders of record as of June 1, 2022. About Bruker Corporation... Read more

Danaher Joins Bespoke Gene Therapy Consortium (BGTC) for Rare Diseases

Consortium aims to speed the development and delivery of customized or ‘bespoke’ gene therapies WASHINGTON, May 12, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it has joined the Bespoke Gene Therapy Consortium (BGTC). Launched in October 2021, the BGTC will generate gene therapy resources that the research community can use to streamline gene... Read more